SG11202011256RA - Aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea - Google Patents
Aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]ureaInfo
- Publication number
- SG11202011256RA SG11202011256RA SG11202011256RA SG11202011256RA SG11202011256RA SG 11202011256R A SG11202011256R A SG 11202011256RA SG 11202011256R A SG11202011256R A SG 11202011256RA SG 11202011256R A SG11202011256R A SG 11202011256RA SG 11202011256R A SG11202011256R A SG 11202011256RA
- Authority
- SG
- Singapore
- Prior art keywords
- phenyl
- dimorpholin
- triazin
- piperidin
- dimethylamino
- Prior art date
Links
- DWZAEMINVBZMHQ-UHFFFAOYSA-N 1-[4-[4-(dimethylamino)piperidine-1-carbonyl]phenyl]-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea Chemical compound C1CC(N(C)C)CCN1C(=O)C(C=C1)=CC=C1NC(=O)NC1=CC=C(C=2N=C(N=C(N=2)N2CCOCC2)N2CCOCC2)C=C1 DWZAEMINVBZMHQ-UHFFFAOYSA-N 0.000 title 1
- 239000013011 aqueous formulation Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862681722P | 2018-06-07 | 2018-06-07 | |
| US201862754651P | 2018-11-02 | 2018-11-02 | |
| US201962796133P | 2019-01-24 | 2019-01-24 | |
| US201962841882P | 2019-05-02 | 2019-05-02 | |
| PCT/IB2019/054643 WO2019234632A1 (en) | 2018-06-07 | 2019-06-04 | Aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202011256RA true SG11202011256RA (en) | 2020-12-30 |
Family
ID=67402968
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202011256RA SG11202011256RA (en) | 2018-06-07 | 2019-06-04 | Aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20210212944A1 (en) |
| EP (2) | EP4249069A3 (en) |
| JP (2) | JP7423200B2 (en) |
| KR (2) | KR102583563B1 (en) |
| CN (2) | CN112218618A (en) |
| AU (2) | AU2019283550B2 (en) |
| BR (1) | BR112020023891A2 (en) |
| CA (1) | CA3102527A1 (en) |
| DK (1) | DK3810089T3 (en) |
| ES (1) | ES2956225T3 (en) |
| FI (1) | FI3810089T3 (en) |
| HR (1) | HRP20231337T1 (en) |
| HU (1) | HUE063493T2 (en) |
| IL (1) | IL279270A (en) |
| LT (1) | LT3810089T (en) |
| MX (2) | MX2020013238A (en) |
| PL (1) | PL3810089T3 (en) |
| PT (1) | PT3810089T (en) |
| RS (1) | RS64692B1 (en) |
| SG (1) | SG11202011256RA (en) |
| SI (1) | SI3810089T1 (en) |
| TW (1) | TWI696469B (en) |
| WO (1) | WO2019234632A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3672571T3 (en) | 2017-08-25 | 2022-01-31 | Pfizer Inc. | Pharmaceutical aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea |
| AU2022320615A1 (en) | 2021-07-26 | 2024-03-14 | Celcuity Inc. | 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea (gedatolisib) and its combinations for use in the treatment of cancer |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4727064A (en) * | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
| US5002935A (en) * | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
| US5298410A (en) * | 1993-02-25 | 1994-03-29 | Sterling Winthrop Inc. | Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life |
| WO2003015828A1 (en) * | 2001-08-20 | 2003-02-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | Parenteral formulations of 1-(5-tert-butyl-2-p-tolyl-2h-pryrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea and a cyclodextrin |
| KR20080068136A (en) * | 2005-11-15 | 2008-07-22 | 백스터 인터내셔널 인코포레이티드 | Compositions comprising lipoxygenase inhibitors and cyclodextrin |
| CA2721710A1 (en) * | 2008-05-23 | 2009-11-26 | Wyeth Llc | Triazine compounds as pi3 kinase and mtor inhibitors |
| WO2010096619A1 (en) | 2009-02-23 | 2010-08-26 | Wyeth Llc | Process, purification and crystallization of 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea |
| AR081364A1 (en) * | 2010-05-05 | 2012-08-29 | Glaxo Wellcome Mfg Pte Ltd | PHARMACEUTICAL COMPOSITIONS OF PAZOPANIB AND METHODS FOR THEIR DEVELOPMENT |
| US20140220112A1 (en) * | 2013-02-01 | 2014-08-07 | Zoneone Pharma, Inc. | Transformation of drug cyclodextrin complex compositions into compositions of mixtures of lipid vesicle encapsulated drug and cyclodextrin drug complexes |
| ME03435B (en) * | 2014-03-14 | 2020-01-20 | Pfizer | Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same |
| PL3233054T3 (en) * | 2014-12-17 | 2021-12-20 | Pfizer Inc. | Formulations of a pi3k/mtor-inhibitor for intravenous administration |
| KR101829705B1 (en) * | 2016-09-21 | 2018-02-19 | 씨제이헬스케어 주식회사 | Composition for injection having improved stability |
| PL3672571T3 (en) * | 2017-08-25 | 2022-01-31 | Pfizer Inc. | Pharmaceutical aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea |
-
2019
- 2019-06-04 HR HRP20231337TT patent/HRP20231337T1/en unknown
- 2019-06-04 WO PCT/IB2019/054643 patent/WO2019234632A1/en active Application Filing
- 2019-06-04 EP EP23176968.8A patent/EP4249069A3/en active Pending
- 2019-06-04 PT PT197428980T patent/PT3810089T/en unknown
- 2019-06-04 CN CN201980037499.4A patent/CN112218618A/en active Pending
- 2019-06-04 PL PL19742898.0T patent/PL3810089T3/en unknown
- 2019-06-04 US US15/734,147 patent/US20210212944A1/en active Pending
- 2019-06-04 ES ES19742898T patent/ES2956225T3/en active Active
- 2019-06-04 SI SI201930595T patent/SI3810089T1/en unknown
- 2019-06-04 MX MX2020013238A patent/MX2020013238A/en unknown
- 2019-06-04 BR BR112020023891-0A patent/BR112020023891A2/en unknown
- 2019-06-04 EP EP19742898.0A patent/EP3810089B1/en active Active
- 2019-06-04 KR KR1020207037914A patent/KR102583563B1/en active IP Right Grant
- 2019-06-04 RS RS20230948A patent/RS64692B1/en unknown
- 2019-06-04 LT LTEPPCT/IB2019/054643T patent/LT3810089T/en unknown
- 2019-06-04 CN CN202310372451.7A patent/CN116270452A/en active Pending
- 2019-06-04 KR KR1020237032620A patent/KR20230142810A/en active Application Filing
- 2019-06-04 CA CA3102527A patent/CA3102527A1/en active Pending
- 2019-06-04 AU AU2019283550A patent/AU2019283550B2/en active Active
- 2019-06-04 DK DK19742898.0T patent/DK3810089T3/en active
- 2019-06-04 HU HUE19742898A patent/HUE063493T2/en unknown
- 2019-06-04 SG SG11202011256RA patent/SG11202011256RA/en unknown
- 2019-06-04 FI FIEP19742898.0T patent/FI3810089T3/en active
- 2019-06-05 JP JP2019105034A patent/JP7423200B2/en active Active
- 2019-06-06 TW TW108119644A patent/TWI696469B/en active
-
2020
- 2020-12-04 MX MX2023012527A patent/MX2023012527A/en unknown
- 2020-12-07 IL IL279270A patent/IL279270A/en unknown
-
2022
- 2022-08-03 AU AU2022211854A patent/AU2022211854B2/en active Active
-
2023
- 2023-08-14 JP JP2023132078A patent/JP2023138872A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016012009A (en) | Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same. | |
| DK3154959T3 (en) | 1 - ((3S, 4R) -4- (3-fluorophenyl) -1- (2-methoxyethyl) pyrrolidin-3-yl) -3- (4-methyl-3- (2-methyl-pyrimidin-5-yl) - 1-PHENYL-1H-PYRAZOL-5-YL) URINE AS A TRKA-KINASE INHIBITOR | |
| IL279914A (en) | High-affinity, isoform-selective tgfβ1 inhibitors and use thereof | |
| IL252368B (en) | 2-(1,5-dimethyl-3-phenyl-1h-pyrrol-2-yl)-n-(4-(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)phenyl)-2-oxoacetamide and pharmaceutical compositions comprising the same | |
| IL279270A (en) | Aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea | |
| NZ719975A (en) | Active compound combinations comprising a (thio)carboxamide derivative and a fungicidal compound | |
| IL291738A (en) | Method for preparing 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)-prop-2-en-1-one hydrochloride and intermediates used therein | |
| EP3626709A4 (en) | Indazole compound for use in inhibiting kinase activity, composition and application thereof | |
| ZA202004311B (en) | Pyrazole amide compound and application thereof, and fungicide | |
| PL3672571T3 (en) | Pharmaceutical aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea | |
| IL243650A0 (en) | 1-(piperazin-1-yl)-2-([1,2,4]triazol-1-yl)-ethanone derivatives | |
| IL239928B (en) | Compositions comprising (s)-1-(4-(3,4-dichlorophenyl)piperidino)-3-(2-(5-methyl-1,3,4-oxadiazol-2-yl)benzo[b]furan-4-yloxy)-2-propanol for treating depression | |
| ZA201801544B (en) | 1-(4-(2-((1-(3,4-difluorophenyl)-1h-pyrazol-3-yl)methoxy)ethyl) piperazin-1-yl)ethanone salts | |
| IL310243A (en) | 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea (gedatolisib) and its combinations for use in the treatment of cancer | |
| UA37000S (en) | CORNER SOFA "BRUNO" | |
| TH1601002081A (en) | Pharmaceutical form comprising sodium 1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazole-1-yl)-1H -pyrazole-5-oleate | |
| UA35578S (en) | CORNER SOFA "M1" | |
| UA35220S (en) | CORNER SOFA "GRETTA" | |
| UA34547S (en) | CORNER SOFA "RAFAELLA" |